The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials
Silvia Oghina(Amyloidosis Foundation), Diane Bodez(Inserm), Wulfran Bougouin(Inserm), Mounira Kharoubi(Inserm), Thibaud Damy(Amyloidosis Foundation), Alain Cohen‐Solal(Inserm), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Michel Komajda(Hôpital Saint Joseph), Mélanie Bézard(Amyloidosis Foundation)
Cited by 88
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k